OSR (OSRH) and Its Rivals Head to Head Review

OSR (NASDAQ:OSRH) is one of 89 public companies in the “UNCLASSIFIED” industry, but how does it contrast to its peers? We will compare OSR to related businesses based on the strength of its profitability, analyst recommendations, risk, earnings, institutional ownership, dividends and valuation.

Valuation and Earnings

This table compares OSR and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
OSR	N/A	-$2.41 million	-0.49
OSR Competitors	$203.60 million	-$18.84 million	93.13

OSR’s peers have higher revenue, but lower earnings than OSR. OSR is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares OSR and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OSR	N/A	-6.66%	-4.90%
OSR Competitors	0.86%	0.95%	0.80%

Insider & Institutional Ownership

55.3% of OSR shares are owned by institutional investors. Comparatively, 51.0% of shares of all “UNCLASSIFIED” companies are owned by institutional investors. 60.6% of OSR shares are owned by company insiders. Comparatively, 42.7% of shares of all “UNCLASSIFIED” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

OSR has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Comparatively, OSR’s peers have a beta of -0.09, indicating that their average stock price is 109% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for OSR and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OSR	1	0	0	0	1.00
OSR Competitors	241	267	217	3	1.98

As a group, “UNCLASSIFIED” companies have a potential upside of 117.65%. Given OSR’s peers stronger consensus rating and higher possible upside, analysts clearly believe OSR has less favorable growth aspects than its peers.

Summary

OSR peers beat OSR on 9 of the 13 factors compared.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.